Center-Authored Papers

Filters: Author is Morishima, Chihiro  [Clear All Filters]
Journal Article
Dietsch GN, Lu H, Yang Y, Morishima C, Chow LQ, Disis ML, Hershberg RM.  2016.  Coordinated Activation of Toll-Like Receptor8 (TLR8) and NLRP3 by the TLR8 Agonist, VTX-2337, Ignites Tumoricidal Natural Killer Cell Activity.. PloS one. 11(2):e0148764. Abstract
Miller JS, Morishima C, McNeel DG, Patel MR, Kohrt HE, Thompson JA, Sondel PM, Wakelee HA, Disis ML, Kaiser JC et al..  2018.  A First-in-Human Phase 1 Study of Subcutaneous Outpatient Recombinant Human IL-15 (rhIL-15) in Adults with Advanced Solid Tumors.. Clinical cancer research : an official journal of the American Association for Cancer Research. 24(7):1525-1535. Abstract
Chow LQM, Morishima C, Eaton KD, Baik CS, Goulart BH, Anderson LN, Manjarrez KL, Dietsch GN, Bryan JK, Hershberg RM et al..  2016.  Phase 1b Trial of the Toll-Like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN.. Clinical cancer research : an official journal of the American Association for Cancer Research. Abstract
Margolin K, Morishima C, Velcheti V, Miller JS, Lee SM, Silk AW, Holtan SG, Lacroix AM, Fling SP, Kaiser JC et al..  2018.  Phase I Trial of ALT-803, a Novel Recombinant Interleukin-15 Complex, in Patients with Advanced Solid Tumors.. Clinical cancer research : an official journal of the American Association for Cancer Research. Abstract
Morishima C, Shuhart MC, Wang CC, Paschal DM, Apodaca MC, Liu Y, Sloan DD, Graf TN, Oberlies NH, Lee DY-W et al..  2010.  Silymarin inhibits in vitro T-cell proliferation and cytokine production in hepatitis C virus infection.. Gastroenterology. 138(2):671-81,681.e1-2. Abstract
Paulson KG, Lewis CW, Redman MW, Simonson WT, Lisberg A, Ritter D, Morishima C, Hutchinson K, Mudgistratova L, Blom A et al..  2016.  Viral oncoprotein antibodies as a marker for recurrence of Merkel cell carcinoma: A prospective validation study.. Cancer. Abstract